Fig. 1

Study design. ^aThe index date was defined as the first medical or pharmacy claim for vedolizumab or ustekinumab during the patient identification period. ^bThe baseline period was defined as the period 6 months before and on the index date. ^cThe follow-up period began on the day after the index date and ended on whichever came first of discontinuation, surgery event, switching or initiation of combination treatment, disenrollment, or the end of the study period